bioAffinity Technologies, Inc. (BIAF) earnings
BIAF earnings moved a median of -0.13% by the close. Quarterly and annual BIAF reports and results, each read against the price at its own news timestamp. Back to the BIAF overview →
23 measured BIAF earnings events.
Where these BIAF earnings landedvs 22 measured BIAF earnings reactions
| Middle 50% of BIAF earnings reactions | -3.75% to +1.38% |
|---|---|
| Median reaction (to close) | -0.13% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 BIAF earnings events with a measured close landed between -3.75% and +1.38%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 | Press release | -2.53% | -7.05% | |
| bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | Press release | -0.47% | -3.77% | |
| Form 10-Q bioAffinity Technologies For: Jun 30 | SEC filing · Form 10-Q | +1.18% | — | |
| Form 10-Q bioAffinity Technologies For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +2.07% | |
| bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung | Press release | -1.89% | -4.25% | |
| Form 10-K bioAffinity Technologies For: Dec 31 | SEC filing · Form 10-K | +2.66% | +1.60% | |
| bioAffinity Technologies Reports Third Quarter 2025 Financial Results | Press release | +1.39% | +2.22% | |
| Form 10-Q bioAffinity Technologies For: Sep 30 | SEC filing · Form 10-Q | +1.16% | -8.67% | |
| bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025 | Press release | +1.21% | -3.16% | |
| bioAffinity Technologies Reports Second Quarter 2025 Results | Press release | +0.94% | -3.70% | |
| Form 10-Q bioAffinity Technologies For: Jun 30 | SEC filing · Form 10-Q | +3.11% | -5.82% | |
| bioAffinity Technologies Reports First Quarter 2025 Results | Press release | -12.33% | -14.33% | |
| Form 10-Q bioAffinity Technologies For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Form 10-K/A bioAffinity Technologies For: Dec 31 | SEC filing · Form 10-K | — | +5.62% | |
| Form 10-K bioAffinity Technologies For: Dec 31 | SEC filing · Form 10-K | -7.06% | +55.71% | |
| Form 10-Q bioAffinity Technologies For: Sep 30 | SEC filing · Form 10-Q | +1.12% | -2.24% | |
| Form 10-Q bioAffinity Technologies For: Jun 30 | SEC filing · Form 10-Q | — | +1.14% | |
| bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung | Press release | -0.60% | +1.20% | |
| bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes | Press release | +0.53% | +1.07% | |
| Form 10-Q bioAffinity Technologies For: Mar 31 | SEC filing · Form 10-Q | — | -0.27% | |
| Form 10-K bioAffinity Technologies For: Dec 31 | SEC filing · Form 10-K | -1.44% | +1.44% | |
| bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +0.00% | -0.35% | |
| Form 10-Q bioAffinity Technologies For: Sep 30 | SEC filing · Form 10-Q | — | +0.00% |
Keep exploring
More BIAF: analyst actions → · SEC filings → · BIAF overview →